Company Overview
About Caidya
Caidya is a global, full-service contract research organization (CRO) formed in 2021 through the merger of dMed Global, a Shanghai-based clinical research firm, and Clinipace Incorporated, a North Carolina-based CRO. The combined entity rebranded as Caidya with a mission to "liberate clinical research" by providing more personalized, knowledge-driven CRO services to biopharmaceutical innovators developing breakthrough therapies for patients with unmet medical needs. Headquartered in Raleigh, North Carolina, Caidya operates across more than 20 countries with study execution capabilities spanning more than 50 countries and regions — including deep expertise in the Americas, Europe, and Asia-Pacific, particularly Mainland China.
Business Model & Competitive Advantage
Caidya's therapeutic expertise is concentrated in oncology, hematology, rare diseases, and pediatric drug development — areas that require specialized clinical trial design, regulatory strategy, and site relationships. In January 2025, Caidya announced a $165 million strategic growth investment from Rubicon Founders, a healthcare-focused investment firm, to accelerate global expansion and deepen its capabilities in high-complexity therapeutic areas. The company has won multiple CRO Leadership Awards for overall capabilities, data quality, and therapeutic expertise.
Competitive Landscape 2025–2026
Caidya differentiates itself from the largest global CROs (IQVIA, Covance, PPD) by operating as a "personalized," mid-sized CRO that provides more senior-level attention, faster decision-making, and deeper regional expertise — particularly in Asia-Pacific markets where regulatory and operational knowledge is critical for multinational pharmaceutical sponsors seeking to run simultaneous global clinical trials.
Key Differentiators
Strong Challenger
Caidya is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare Caidya with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Caidya? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Caidya Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Caidya vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →